ExploreWatchlistsPricing
  1. US-listed companies
  2. IMMUNIC, INC.
  3. Financials
  4. EBITDA

IMMUNIC, INC. (IMUX)

Market cap
$1.3B
P/E ratio
SummaryFinancials
Period EndEBITDA (Million USD)YoY (%)
Dec 31, 2025-103+5.25%
Dec 31, 2024-98-1.20%
Dec 31, 2023-99-17.00%
Dec 31, 2022-119+30.39%
Dec 31, 2021-92+87.16%
Dec 31, 2020-49+32.31%
Dec 31, 2019-37-10.45%
Dec 31, 2018-41-20.06%
Dec 31, 2017-52+30.92%
Dec 31, 2016-39-22.31%
Dec 31, 2015-51+3.12%
Dec 31, 2014-49

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat